TY - CHAP
T1 - Effect of methotrexate treatment for ectopic pregnancy on current and subsequent pregnancy
AU - Namouz-Haddad, Shirin
AU - Koren, Gideon
N1 - Publisher Copyright:
© Springer International Publishing Switzerland 2015.
PY - 2015/1/1
Y1 - 2015/1/1
N2 - Methotrexate (MTX), a folic acid antagonist and DNA synthesis inhibitor in rapidly dividing cells, has been implicated in as a human teratogen, particularly when used in a high dose during the first trimester of pregnancy. Erroneous MTX treatment during pregnancy should prompt a thorough discussion and counseling of the patient regarding the risks of fetal exposure to MTX. Following MTX treatment, a 6-month interval before conception following the treatment should be advised. However, conception within less than 3–6 months subsequent to MTX treatment should not be considered as a definite indication for pregnancy termination.
AB - Methotrexate (MTX), a folic acid antagonist and DNA synthesis inhibitor in rapidly dividing cells, has been implicated in as a human teratogen, particularly when used in a high dose during the first trimester of pregnancy. Erroneous MTX treatment during pregnancy should prompt a thorough discussion and counseling of the patient regarding the risks of fetal exposure to MTX. Following MTX treatment, a 6-month interval before conception following the treatment should be advised. However, conception within less than 3–6 months subsequent to MTX treatment should not be considered as a definite indication for pregnancy termination.
KW - Aminopterin syndrome
KW - Methotrexate embryopathy
KW - Methotrexate toxicity
KW - Teratogen
UR - http://www.scopus.com/inward/record.url?scp=84944618182&partnerID=8YFLogxK
U2 - 10.1007/978-3-319-11140-7_10
DO - 10.1007/978-3-319-11140-7_10
M3 - ???researchoutput.researchoutputtypes.contributiontobookanthology.chapter???
AN - SCOPUS:84944618182
SN - 9783319111391
SP - 69
EP - 75
BT - Ectopic Pregnancy
ER -